Peptide education
Selank
Selank is a seven-amino-acid peptide built on tuftsin, a natural immune peptide, with a Pro-Gly-Pro tail added to slow breakdown. Russia sells it as a 0.15% nasal-drop medicine for anxiety disorders, and small Russian trials compared it against actual benzodiazepines, which already puts it ahead of most gray-market peptides. What the internet added is the nootropic framing: calm focus, brain fog, mood, benzodiazepine-level calm without benzodiazepine problems. The trials were small, old, and never replicated outside Russia, so that bigger reputation rests on thin ground.
Selank is one of the few gray-market peptides with human comparator trials behind it: small Russian studies against medazepam and phenazepam for anxiety. Everything past that, the nootropic calm, the BDNF story, the benzodiazepine benefits without benzodiazepine risks, is extrapolation.
Overview
Quick answer
Selank does not mean the same product everywhere. The Russian registered product is a 0.15% intranasal nasal-drop medicine. Public chemistry records also list Selank acetate and Selank diacetate, and the market often blurs parent peptide, salt form, nasal sprays, lyophilized powders, and related derivatives such as N-acetyl Selank. Those differences change what can be inferred about dose, exposure, stability, and safety.
What is it?
Selank is a synthetic heptapeptide, TKPRPGP, derived from the immune peptide tuftsin with a Pro-Gly-Pro tail added for stability. In Russia it is a registered intranasal anxiolytic. In the U.S. it is an unapproved spray or powder borrowing that reputation.
What do people use it for?
The Russian label covers generalized anxiety, neurasthenia, and adjustment disorders, and the small trials stayed in that anxiety-spectrum territory. Online, the same name gets used for calm focus, stress tolerance, brain fog, mood, and non-sedating productivity, a much broader brief than the studies ever carried.
What route, amount, and schedule details do sources report?
The only official schedule is the Russian one: 0.15% nasal drops, 2 drops per nostril three times daily for 14 days, with repeat courses after a 1 to 3 week break. Community reports describe 250 to 500 mcg intranasally one to three times daily, or 250 to 300 mcg injected subcutaneously, but nothing studied stands behind those numbers.
Is it a nootropic?
Not on the evidence shown here. The human cognition data amount to one 52-person fMRI study measuring resting-state connectivity, not memory, focus, or brain-fog outcomes. The BDNF and learning-memory findings are rodent and cell work.
What limits the evidence and product claims?
Three things. The trials are small, old, Russian-language, and short on published design detail. Nothing has replicated them outside that literature. And the U.S. market sells salt forms, sprays, and powders with no Russian label behind them, while FDA flags specific safety concerns for compounded Selank acetate.
Reported practice
Commonly reported protocol
Intranasal community ranges. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Small older Russian human studies reported anxiolytic effects in generalized anxiety disorder, neurasthenia, phobic-anxiety, somatoform, and related anxiety-spectrum settings.
Russian state-register materials describe a 0.15% nasal-drop product with generalized anxiety disorders, neurasthenia, and adjustment disorders among labeled indications, plus a 14-day nasal-drop schedule in the cited label context.
A healthy-volunteer fMRI study supports human mechanistic interest, but it is not a clinical focus, memory, brain-fog, ADHD, or performance outcome.
FDA materials and warning-letter history identify U.S. non-approval, compounding concerns, intended-use risk, and specific safety concerns for compounded Selank acetate.
Russian labeling contraindicates pregnancy and breastfeeding because necessary controlled safety data are lacking, and reports no use experience in people under 18. Native Selank labeling does not answer questions about gray-market products, derivative forms, or other populations.
Clinic and vendor pages market Selank for calm, focus, mood, stress, and brain-fog themes, while forensic and COA material shows why open online availability is not the same as dependable medicine-quality supply.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Selank helps anxiety. | Anxiety is the strongest Selank claim. Zozulia 2008, Medvedev 2014, and Medvedev 2015 reported anxiety-related benefits in small Russian human studies using medazepam, phenazepam, or add-on comparison contexts. | GABA-related modulation, enkephalin-degradation effects, monoamine signaling, and tuftsin-related biology give a plausible anxiety rationale, while the exact human mechanism remains a live question. | Clinics, wellness sellers, forums, and marketplace discussion commonly describe Selank for stress relief, calm focus, emotional balance, and anxiety-like symptoms. | Small Russian anxiety studies and label history support anxiety-context discussion. Broad immune, cognition, benzodiazepine-replacement, and U.S.-therapy claims need their own evidence; they do not follow automatically from the anxiety studies. |
| Selank improves focus, memory, cognition, or brain fog. | The human cognition evidence is weak. A 52-participant fMRI study in healthy volunteers reported resting-state connectivity effects, but that is not a patient-level cognition outcome. | Rodent and cell work connects Selank to BDNF expression, serotonin metabolism, dopamine-related genes, learning and memory signals, and GABAergic pathways. | Clinic pages and online discussions often market Selank as a clear-headed or non-sedating nootropic, especially for brain fog, stress performance, and productivity. | Cognition remains a secondary claim. The biology is plausible, but the human evidence is too limited to call Selank a nootropic treatment. |
| Selank works like a benzodiazepine without benzodiazepine downsides. | The Medvedev studies reported favorable short-term tolerability themes against phenazepam or in phenazepam add-on use, and Zozulia compared Selank with medazepam. Those studies do not settle long-term dependence, withdrawal, rebound anxiety, sedation, interaction, or psychiatric-safety questions. | GABA-related hypotheses explain why people make benzodiazepine comparisons, but the mechanistic literature still leaves pharmacology and risk meaningfully different from benzodiazepine evidence. | Marketing often turns "non-sedating calm" into a broad safety claim. Forum and clinic discussion can show demand for that idea, but it cannot settle dependence, withdrawal, sedation, interaction, or long-term psychiatric risk. | The available comparator studies do not establish Selank as dependency-free or risk-free. The short-term signals exist, but they do not make Selank a blanket benzodiazepine alternative. |
| Selank raises BDNF or improves neuroplasticity. | Current human studies have not reported Selank raising BDNF in people or producing clinically meaningful neuroplasticity benefits. | A rat study reported hippocampal BDNF-expression regulation after intranasal Selank, and other preclinical papers reported monoamine and learning-memory related effects. | Nootropic marketing often uses BDNF and neuroplasticity language to support focus, memory, or brain-optimization claims. | This is preclinical mechanism language, not a human BDNF or cognitive-enhancement result. |
| Selank boosts immunity. | Uchakina 2008 reported immunomodulatory effects in patients with anxiety-asthenic disorders, but the public abstract does not report a clinical immune-outcome result. | Tuftsin lineage, cytokine-regulating reports, and cell or transcriptomic work support immune-pathway interest. | Vendor and wellness claims may translate immune-pathway language into general immune support. | The evidence supports mechanism and biomarker discussion, not broad immune-boosting claims without condition-specific human data. |
| Selank is FDA-approved or standard U.S. peptide therapy. | The sources identify Russian registration, not a U.S. FDA-approved Selank product. | Mechanistic interest does not determine U.S. approval, compounding eligibility, or finished-product quality. | U.S. clinic, vendor, and research-use pages can make Selank look clinically ordinary, but FDA warning and compounding materials point in a different direction. | Not for the United States. Any approval language needs to be jurisdiction-specific to Russia. |
Bottom line
Main takeaway
Selank is a Russian anti-anxiety nasal spray with small human trials behind it, which is unusual in this market. It is not a proven nootropic, and U.S. products are not the studied medicine.
Separate the claims by source. Anxiety rests on Russian comparator trials and a domestic label; cognition rests on one fMRI study and rodent work; the benzodiazepine-without-downsides idea rests on short-term tolerability signals, not dependence or withdrawal data.
The old papers lack published regimen detail, and there are no modern placebo-controlled trials, no human pharmacokinetics, and no dependence or withdrawal data. Start with Zozulia 2008, the two Medvedev studies, and the Panikratova fMRI paper.
Identity
What it is
Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a synthetic analog of tuftsin, the body's own immunomodulatory tetrapeptide, extended with a Pro-Gly-Pro tail that Russian investigators describe as improving metabolic stability.
In Russia it is a pharmacy product: 0.15% nasal drops labeled for generalized anxiety disorders, neurasthenia, and adjustment disorders, taken three times daily for 14 days. The supporting human studies are small domestic trials comparing Selank with medazepam or phenazepam, plus one healthy-volunteer fMRI study.
Outside Russia the name floats free of that product. Sprays, lyophilized powders, acetate and diacetate salts, and N-acetyl derivatives all get sold as Selank, usually with cognition and mood language the Russian trials never tested.
How people talk about it online
Clinic and wellness pages sell Selank as calm without sedation: stress relief, clear thinking, emotional balance, brain fog. That is marketing built on a small anxiety literature, not a description of trial results.
Forums treat it as a nootropic and frequently pair it with Semax, sometimes in the same spray schedule. The anxiety evidence gets cited in those threads; the untested cognition claims usually get a pass.
Research-use listings and COAs document how Selank is sold, not what it does. FDA materials flag compounded Selank acetate for immunogenicity risk from aggregation and impurities, so the paperwork question is not academic.
Use context
Routes, doses, and cycle patterns
The clearest schedule belongs to native Selank nasal drops in Russian label material. Russian labeling describes a 0.15% intranasal nasal-drop medicine for anxiety-related indications with 2 drops in each nasal passage, 3 times daily, for 14 days. The cited Russian label describes possible repeat courses after 1 to 3 weeks in that label context. Real-world sources also discuss sprays, lyophilized powders, and informal cycling, but those products do not inherit the Russian label schedule.
Human studies and product labels
Russian registered nasal-drop product
- Purpose
- Generalized anxiety disorders, neurasthenia, and adjustment disorders
- Context
- Russian state-register / label materials
- Route
- Intranasal nasal drops
- Amount
- 0.15% formulation; 2 drops in each nasal passage
- Frequency
- 3 times daily
- Duration
- 14-day course; cited Russian label describes possible repeat courses after 1 to 3 weeks
The Russian nasal-drop label is the clearest official product context. It is Russia-specific and says nothing about U.S. approval status or the quality of unrelated salt forms, powders, sprays, or derivative products.
Zozulia 2008 anxiety and neurasthenia study
- Purpose
- Generalized anxiety disorder and neurasthenia
- Context
- Human comparator study
- Route
- Not stated in the public abstract
- Amount
- Not stated in the public abstract
- Frequency
- Not stated in the public abstract
- Duration
- Not stated in the public abstract
The 62-patient comparison reported similar anxiolytic effects versus medazepam, plus antiasthenic and psychostimulant effects. The summary does not give enough regimen detail or modern trial-quality context.
Medvedev 2014 phenazepam comparison
- Purpose
- Phobic-anxiety and somatoform disorders
- Context
- Human comparator study
- Route
- Not stated in the public abstract
- Amount
- Not stated in the public abstract
- Frequency
- Not stated in the public abstract
- Duration
- Not stated in the public abstract
The 60-patient comparison reported pronounced anxiolytic and mild nootropic effects, with better tolerability than phenazepam. The result is relevant, but too limited for benzodiazepine-equivalent efficacy or settled long-term safety.
Medvedev 2015 phenazepam add-on study
- Purpose
- Anxiety-disorder treatment optimization
- Context
- Human adjunct study
- Route
- Not stated in the public abstract
- Amount
- Not stated in the public abstract
- Frequency
- Not stated in the public abstract
- Duration
- Not stated in the public abstract
The 70-patient study compared phenazepam alone with phenazepam plus Selank and reported earlier improvement on HDRS and fewer selected phenazepam side effects in the combination arm. Adjunct data cannot isolate Selank on its own.
Healthy-volunteer fMRI study
- Purpose
- Mechanistic brain-connectivity signal
- Context
- Human mechanistic study
- Route
- Route detail not available from the cited summary.
- Amount
- Dose detail not available from the cited summary.
- Frequency
- Schedule detail not available from the cited summary.
- Duration
- Course length not available from the cited summary.
The 52-participant fMRI study examined Selank and Semax effects on resting-state functional connectivity. It supports mechanistic human interest, not a clinical cognition or anxiety efficacy claim.
Real-world discussion
Intranasal community ranges
- Purpose
- Anxiety and cognition discussion
- Context
- Nootropic community, vendors, and forums
- Route
- Intranasal spray or drops
- Amount
- Commonly around 250 to 500 mcg per administration, one to three times daily.
- Frequency
- One to three times daily, commonly morning or early afternoon
- Duration
- Often described as 10 to 14 day courses, sometimes repeated after a break
Community ranges derive loosely from the Russian intranasal product literature; controlled human outcome data outside that literature are sparse. Reported as context, not a recommendation.
Subcutaneous community ranges
- Purpose
- Anxiety and cognition discussion
- Context
- Forums and protocol blogs
- Route
- Subcutaneous injection
- Amount
- Commonly around 250 to 300 mcg once daily
- Frequency
- Once daily in most reports
- Duration
- Often described in 2 to 4 week runs
Injectable use is community practice without a studied human basis; product identity in vials is unverified.
What varies
- Jurisdiction: Russian registration is different from U.S. FDA status.
- Route: intranasal drops, nasal sprays, and lyophilized powders are not dose-equivalent.
- Amount: the native Russian label gives nasal-drop context, while the available human-study records and market examples do not supply a reliable schedule for sprays, powders, injected products, or derivatives.
- Product form: parent Selank, acetate, diacetate, and related derivatives need separate identity checks.
- Quality: COA purity, research-use labeling, sterility, endotoxin testing, excipients, and chain of custody are separate issues.
Human data
Human evidence
Selank has human evidence, which already distinguishes it in this market, but the evidence is small, old, and domestic: three Russian anxiety-spectrum studies totaling about 190 patients, one immunology biomarker paper, and a 52-person fMRI study in healthy volunteers. The comparator trials reported anxiolytic effects similar to medazepam and better tolerability than phenazepam, and all of it grades weak here because published design detail is thin. Nothing outside Russia has replicated those results, and there is no patient-level cognition trial at all.
Evidence maturity
Selank's evidence is a domestic literature: real but small Russian studies, and nothing Western-controlled.
Developed as an intranasal anxiolytic from the tuftsin lineage.
Small Russian trials and registrations behind the anxiolytic claims.
None; no controlled trials outside that literature.
Vendor-modified amidated analogs with no published evidence at all.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Zozulia 2008 GAD and neurasthenia study | 62 patients with generalized anxiety disorder and neurasthenia | Human comparator study | Russian investigational or clinical Selank context | The public summary reported anxiolytic effects similar to medazepam, plus antiasthenic and psychostimulant effects and serum enkephalin-related measurements. | The public abstract does not provide enough detail on blinding, randomization, exact regimen, adverse events, or modern risk-of-bias assessment. | weak |
| Uchakina 2008 immunomodulatory paper | Patients with anxiety-asthenic disorders | Human biomarker paper | Russian Selank research context | Reported cytokine-regulating or immunotropic effects in an anxiety-asthenic population. | This supports immune-pathway interest, not an observed clinical immune benefit or a general immune-support claim. | weak |
| Medvedev 2014 Selank versus phenazepam comparison | 60 patients with phobic-anxiety and somatoform disorders | Human comparator study | Russian clinical research context | Reported pronounced anxiolytic and mild nootropic effects, persistence of effect for about a week after final administration, and tolerability advantages versus phenazepam. | Russian-language paper with limited public design detail; weaker than a modern multinational placebo-controlled trial. | weak |
| Medvedev 2015 Selank plus phenazepam study | 70 anxiety-disorder patients split between phenazepam monotherapy and Selank plus phenazepam | Human adjunct study | Russian clinical research context | Reported earlier positive effects on HDRS and lower burden of several phenazepam-related side effects in the combination arm. | The adjunct design does not provide stand-alone Selank efficacy data. Exact regimen details were not recovered from the available abstracts. | weak |
| Panikratova 2020 Selank and Semax fMRI study | 52 healthy participants | Human mechanistic imaging study | Research setting | Reported resting-state functional-connectivity effects in predefined brain regions after Selank and Semax exposure. | Healthy-volunteer imaging supports mechanism. Anxiety, cognition, ADHD, depression, PTSD, and brain-fog outcomes are separate clinical questions. | weak |
Cautions
Safety and unknowns
- Russian labeling contraindicates pregnancy and breastfeeding because necessary controlled safety data are lacking, and it reports no use experience in people under 18.
- The small comparator studies do not settle long-term psychiatric safety, dependence, withdrawal, rebound anxiety, sedation, interaction risk, or repeated intranasal tolerability.
- FDA states that compounded Selank acetate may pose immunogenicity risk from aggregation and peptide-related impurities and that important human safety information is lacking.
- Salt form, formulation, excipients, route, and product origin may change exposure and risk. Russian nasal drops, clinic products, vendor powders, and research-use products carry separate safety profiles.
- Claims about "no side effects," "no dependence," or guaranteed non-sedating calm go beyond the available human safety evidence.
Product quality
A vial label is only a starting point
Gray-market quality is central for Selank because real-world exposure often appears through research-use products, online marketplaces, nasal sprays, lyophilized powders, and clinic or vendor supply chains.
A forensic drug-testing paper documented seized preparations containing Selank and Semax and noted open online availability of similar nootropic peptides.
Representative COAs can address identity, purity, potency, or composition while still omitting particulate matter, microbial contamination, or endotoxin information.
Illegal injectable peptide contamination literature is not Selank-specific but is relevant to the risk of trusting peptide powders or vials from weakly documented supply chains.
Identity and salt form
Selank, Selank acetate, Selank diacetate, and N-acetyl derivatives can be marketed together even when they are not the same product.
Sterility and endotoxin
Purity by HPLC does not answer whether a nasal or injectable product is free of microbial contamination, endotoxin, or particulate matter.
Concentration and excipients
COA examples may report peptide content and excipient ratios that matter for dose math and comparability.
Chain of custody
A COA is only as useful as the sampling, lot control, storage, shipping, and product-matching practices behind it.
Mechanism
How it is proposed to work
Selank is proposed to affect anxiety and cognition-adjacent biology through several pathways rather than one simple receptor explanation: GABA-related signaling, endogenous enkephalin degradation, monoamine systems, BDNF-related neuroplasticity signals, and tuftsin-linked immune pathways.
GABAergic work includes receptor-binding and gene-expression studies, but cell data partly temper the claim because Selank alone did not always change the studied GABAergic genes.
Enkephalinase inhibition gives a plausible endogenous-peptide mechanism for anxiolytic interest and connects to the human study that measured serum enkephalin-related activity.
BDNF, serotonin, dopamine-related, and learning-memory signals come mostly from rodent or cell work and remain short of human cognitive-enhancement evidence.
Tuftsin origin and cytokine findings explain why immune-related claims appear, but clinical immune benefits have not been shown.
FAQ
Common questions
What is selank used for?
Selank is a Russian-developed intranasal anxiolytic peptide, discussed for anxiety, stress resilience, and mild cognitive support. Its human evidence is small domestic studies from that literature.
How do people typically use it?
Commonly 250 to 500 mcg intranasally, one to three times daily, often in 10 to 14 day courses. Subcutaneous use around 250 to 300 mcg daily is also reported.
Is selank proven?
Not by Western-controlled standards. The supporting trials are Russian and small, and the vendor-modified analogs sold alongside it have no published evidence at all.
Details
Technical details
Sources
References
- 1.
PubChem identity pages. PubChem identity pages for Selank and labeled salt forms.
Chemical identity, sequence, MW, salt normalization
- 2.
Zozulia 2008 anxiety study. Zozulia 2008 human study in GAD and neurasthenia.
Main early human anxiolytic signal
- 3.
Uchakina 2008 immune paper. Uchakina 2008 immunomodulatory human paper.
Immune/cytokine signal in humans
- 4.
Medvedev 2015 add-on study. Medvedev 2015 Selank + phenazepam study.
Adjunct signal and reported side-effect reduction
- 5.
Panikratova 2020 fMRI study. Panikratova 2020 healthy-participant fMRI study.
Human mechanistic signal, not efficacy
- 6.
Volkova 2016 qPCR paper. Volkova 2016 rat frontal-cortex qPCR paper.
GABA-related transcriptomic hypothesis
- 7.
Filatova 2017 cell paper. Filatova 2017 IMR-32 cell paper.
Important corrective nuance on mechanism
- 8.
GABA-modulation papers. Vyunova 2014 receptor-interaction paper and 2018 molecular review.
GABA-binding and allosteric-modulation hypothesis
- 9.
Enkephalinase paper. Zozulya 2001 enkephalinase paper.
Proposed endogenous-peptide mechanism
- 10.
BDNF rat paper. Inozemtseva 2008 BDNF rat paper.
BDNF claim is limited to preclinical context
- 11.
Rodent monoamine papers. Semenova 2009 and 2010 rodent monoamine / memory papers.
Serotonin and cognition-adjacent preclinical support
- 12.
FDA Tailor Made warning letter. FDA Tailor Made warning letter.
Selank named in 503A ineligible compounding context
- 13.
FDA 2026 safety-risk page. FDA 2026 safety-risk page.
FDA safety concerns, “nominated but withdrawn,” inadequate safety information
- 14.
FDA bulks-list pages. FDA bulks-list and compounding-criteria pages.
503A and 503B bulk-substance context
- 15.
FDA internet-sale enforcement. FDA internet-sale and intended-use enforcement examples.
Research-use wording does not answer product quality
- 16.
Vanhee seized-preparation paper. Vanhee 2020 seized-preparation paper.
Gray-market supply-chain evidence
- 17.
Illegal peptide sterility case. Janvier 2018 Bacillus cereus case report.
Sterility risk signal for illegal peptide products
- 18.
Representative Selank COAs. Two representative modern Selank COAs.
Purity-only COA limits and excipient/content variability
- 19.
FTC claim guidance. FTC Health Products Compliance Guidance.
Standard for health-claim substantiation
- 20.
Clinic claim examples. Clinic and wellness claim examples.
Claim mapping only; no efficacy data
- 21.
Marketplace and anecdote signals. Marketplace and anecdote signals.
Consumer-discussion mapping only